IPCA Laboratories Ltd launches Diulcus to address Diabetic Foot Ulcer (DFU) in India

 

 Diulcus, developed by NovaLead Pharma, shows promising results in clinical trials with a 77.20% ulcer closure rate

 Approved by CDSCO and partially funded by BIRAC

by Priya Jadhav

Mumbai, August , 2024: As per the ICMR-INDIAB (2023) study, 10 crore people in India suffer from diabetes, with an additional 13.6 crore people affected by pre-diabetes. This significant health concern positions India to become the diabetes capital of the world by 2030.

In response to this serious healthcare challenge, IPCA Laboratories Ltd proudly announces the launch of Diulcus, a novel product aimed at addressing the challenges of Diabetic Foot Ulcer (DFU) in the Indian market. Diulcus, developed by NovaLead Pharma Pvt Ltd, a pioneer in drug repurposing, represents a significant advancement in the management of DFU. The product has received approval from the Central Drugs Standard Control Organization (CDSCO) and was partially funded by the Biotechnology Industry Research Assistance Council (BIRAC), a Government of India enterprise.

The launch event was graced by esteemed personalities, including Sri. Premchand Godha, Sri AK Jain, Dr. Anil Pareek, Sri Sunil Ghai, and Sri. Supreet Deshpande.

During phase 3 trials in India, Diulcus demonstrated remarkable efficacy, with a 60.3% ulcer closure rate within three months of treatment. Remarkably, patients continued to show an ulcer closure rate of 77.20% over six months, even after stopping treatment at three months. These results are among the best observed for any pharmaceutical preparation used in DFU treatment.

Mr. Premchand Godha, Executive Chairman of IPCA Laboratories Ltd, expressed his enthusiasm about the launch, stating, “With over 15% of diabetic patients suffering from DFU at least once in their lifetime, DFU is the most prevalent complication caused by chronic diabetes. The approval of this patented repurposed drug is significant because DFU is the leading cause for lower limb amputations globally. We are delighted to partner with NovaLead Pharma Pvt Ltd through an IP licensing arrangement to bring Diulcus® for DFU patients in India. It demonstrates IPCA’s commitment towards the patients suffering from unmet medical need and its focus on the diabetes therapy.” Diulcus will be made available to the patients of DFU by Ipca Laboratories Ltd. (Ipca) through an exclusive IP licensing arrangement with NovaLead for Indian starting August 2024.

About Diabetic Foot Ulcer (DFU) :Over 537 million adults are living with diabetes globally and the number is predicted to rise to 643 million by 2030. About 15% of diabetics suffer from DFU, at least once in lifetime, with 25% of DFUs eventually requiring amputation. DFU is a leading cause of lower extremity amputation. The five-year mortality post amputation is 46%. DFU is a serious disease with very limited drug options and very high cost of treatment.

About Diulcus@ (Esmolol Ilydrochloride): Diulcus@ is a prescription medicine used to treat people with diabetic foot ulcer with no clinical infection. Infected DFUs need to be first treated for infection if existing and then put on Diulcus@ treatment for wound closure. A doctor will perform independent assessment of DFU extent to determine the dose to be applied topically on the patient’s DFU. Treating clinicians are advised to refer to the full prescribing information of Diulcus@.

About Ipca Laboratories Ltd (Ipca) :Ipca is a fully integrated pharmaceutical company with a strong thrust on exports. Ipca is vertically integrated and produces Finished Dosage Forms (FDFs) and Active Pharmaceutical Ingredients (APIs).